Academic journal article Bulletin of the World Health Organization

R&D for Affordable Treatment

Academic journal article Bulletin of the World Health Organization

R&D for Affordable Treatment

Article excerpt

Research and development (R&D) projects for hepatitis C, which affects 130 to 150 million people worldwide, and mycetoma, a chronic inflammation, will soon be launched, according to the new business plan of the Drugs for Neglected Diseases initiative (DNDi).

The partnership also said it would create an internal task force with WHO to look into establishing an R&D initiative to develop new antibiotics, given growing antibiotic resistance worldwide and the dearth of new candidate antibiotics in the drugs pipeline.

New effective drugs for hepatitis C are prohibitively expensive especially for people in low- and middle-income countries and an estimated 500 000 people die worldwide every year from hepatitis C-related liver diseases.

To develop affordable treatment for hepatitis C infection, DNDi said it would conduct clinical trials for drug combinations consisting of recently approved drugs in middle-income countries.

"The high cost of a new generation of drugs for hepatitis C has become one of the world's most pressing and high-profile public health challenges, leaving millions of patients behind," DNDi said. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.